• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PTPN2 抑制抗原交叉呈递后 CD8⁺ T 细胞的反应,以维持小鼠外周耐受。

PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.

机构信息

Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.

Swiss Vaccine Research Institute, Epalinges, Switzerland.

出版信息

J Autoimmun. 2014 Sep;53:105-14. doi: 10.1016/j.jaut.2014.05.008. Epub 2014 Jul 2.

DOI:10.1016/j.jaut.2014.05.008
PMID:24997008
Abstract

Antigen cross-presentation by dendritic cells is crucial for priming cytotoxic CD8(+) T cells to invading pathogens and tumour antigens, as well as mediating peripheral tolerance to self-antigens. The protein tyrosine phosphatase N2 (PTPN2) attenuates T cell receptor (TCR) signalling and tunes CD8(+) T cell responses in vivo. In this study we have examined the role of PTPN2 in the maintenance of peripheral tolerance after the cross-presentation of pancreatic β-cell antigens. The transfer of OVA-specific OT-I CD8(+) T cells (C57BL/6) into RIP-mOVA recipients expressing OVA in pancreatic β-cells only results in islet destruction when OVA-specific CD4(+) T cells are co-transferred. Herein we report that PTPN2-deficient OT-I CD8(+) T cells transferred into RIP-mOVA recipients acquire CTL activity and result in β cell destruction and the development of diabetes in the absence of CD4(+) help. These studies identify PTPN2 as a critical mediator of peripheral T cell tolerance limiting CD8(+) T cell responses after the cross-presentation of self-antigens. Our findings reveal a mechanism by which PTPN2 SNPs might convert a tolerogenic CD8(+) T cell response into one capable of causing the destruction of pancreatic β-cells. Moreover, our results provide insight into potential approaches for enhancing T cell-mediated immunity and/or T cell adoptive tumour immunotherapy.

摘要

树突状细胞的抗原交叉呈递对于激活细胞毒性 CD8(+) T 细胞以应对入侵病原体和肿瘤抗原,以及介导对自身抗原的外周耐受至关重要。蛋白酪氨酸磷酸酶 N2(PTPN2)可减弱 T 细胞受体(TCR)信号,并在体内调节 CD8(+) T 细胞的反应。在这项研究中,我们研究了 PTPN2 在胰腺 β 细胞抗原交叉呈递后维持外周耐受中的作用。将 OVA 特异性 OT-I CD8(+) T 细胞(C57BL/6)转移到仅在胰腺 β 细胞中表达 OVA 的 RIP-mOVA 受体中,只有在共转移 OVA 特异性 CD4(+) T 细胞时才会导致胰岛破坏。在此,我们报告说,缺乏 PTPN2 的 OT-I CD8(+) T 细胞转移到 RIP-mOVA 受体中会获得 CTL 活性,并导致β细胞破坏和糖尿病的发展,而无需 CD4(+) 帮助。这些研究确定了 PTPN2 是外周 T 细胞耐受的关键介质,限制了自身抗原交叉呈递后 CD8(+) T 细胞的反应。我们的发现揭示了一种机制,即 PTPN2 SNPs 可能将耐受的 CD8(+) T 细胞反应转化为能够导致胰腺β细胞破坏的反应。此外,我们的结果为增强 T 细胞介导的免疫和/或 T 细胞过继性肿瘤免疫疗法提供了新的见解。

相似文献

1
PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.PTPN2 抑制抗原交叉呈递后 CD8⁺ T 细胞的反应,以维持小鼠外周耐受。
J Autoimmun. 2014 Sep;53:105-14. doi: 10.1016/j.jaut.2014.05.008. Epub 2014 Jul 2.
2
Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.活化的CD4+辅助性T细胞直接刺激野生型和MHC II基因敲除的C57BL/6小鼠以及表达胰岛β细胞卵清蛋白抗原的转基因RIP-mOVA小鼠体内的CD8+细胞毒性T淋巴细胞反应,从而导致糖尿病。
Autoimmunity. 2008 Nov;41(7):501-11. doi: 10.1080/08916930802069256.
3
CD8(+) T cells specific for beta cells encounter their cognate antigens in the islets of NOD mice.对β细胞具有特异性的CD8(+) T细胞在非肥胖糖尿病(NOD)小鼠的胰岛中遇到其同源抗原。
Eur J Immunol. 2009 Oct;39(10):2716-24. doi: 10.1002/eji.200939408.
4
Acquired pMHC I complexes greatly enhance CD4(+) Th cell's stimulatory effect on CD8(+) T cell-mediated diabetes in transgenic RIP-mOVA mice.在转基因RIP-mOVA小鼠中,获得性pMHC I复合物极大地增强了CD4(+) Th细胞对CD8(+) T细胞介导的糖尿病的刺激作用。
Cell Mol Immunol. 2008 Dec;5(6):407-15. doi: 10.1038/cmi.2008.51.
5
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.T 细胞中 PTPN2 磷酸酶缺失可促进实体瘤中的抗肿瘤免疫和 CAR T 细胞疗效。
EMBO J. 2020 Jan 15;39(2):e103637. doi: 10.15252/embj.2019103637. Epub 2019 Dec 5.
6
Cross-presentation of self antigens to CD8+ T cells: the balance between tolerance and autoimmunity.自身抗原向CD8 + T细胞的交叉呈递:耐受性与自身免疫之间的平衡。
Novartis Found Symp. 1998;215:172-81; discussion 181-90. doi: 10.1002/9780470515525.ch13.
7
CD8-T Cells With Specificity for a Model Antigen in Cardiomyocytes Can Become Activated After Transverse Aortic Constriction but Do Not Accelerate Progression to Heart Failure.心肌细胞模型抗原特异性 CD8-T 细胞在主动脉缩窄后可被激活,但不能加速心力衰竭的进展。
Front Immunol. 2018 Nov 15;9:2665. doi: 10.3389/fimmu.2018.02665. eCollection 2018.
8
Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.摄取抗原特异性树突状细胞释放的外泌体的非特异性CD4(+) T细胞刺激抗原特异性CD8(+) CTL反应和长期T细胞记忆。
J Leukoc Biol. 2007 Oct;82(4):829-38. doi: 10.1189/jlb.0407249. Epub 2007 Jul 11.
9
Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.抗原特异性B细胞对免疫刺激复合物相关同源抗原的同时呈递和交叉呈递。
Eur J Immunol. 2008 May;38(5):1238-46. doi: 10.1002/eji.200737758.
10
Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.解剖位置决定了树突状细胞在响应静脉注射可溶性抗原时向T细胞呈递抗原的过程。
Eur J Immunol. 2007 Jun;37(6):1453-62. doi: 10.1002/eji.200636544.

引用本文的文献

1
Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP.蛋白酪氨酸磷酸酶在T细胞中的负调控的免疫治疗意义:PTP1B和TCPTP的新情况
Front Med (Lausanne). 2024 Apr 19;11:1364778. doi: 10.3389/fmed.2024.1364778. eCollection 2024.
2
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity.小分子抑制剂 PTP1B 和 PTPN2 增强 T 细胞抗肿瘤免疫。
Nat Commun. 2023 Jul 27;14(1):4524. doi: 10.1038/s41467-023-40170-8.
3
Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy.
小分子 PTPN2 抑制剂增敏耐药黑色素瘤对抗 PD-1 免疫治疗的反应。
Cancer Res Commun. 2023 Jan 24;3(1):119-129. doi: 10.1158/2767-9764.CRC-21-0186. eCollection 2023 Jan.
4
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.靶向蛋白磷酸酶治疗癌症免疫治疗和自身免疫性疾病。
Nat Rev Drug Discov. 2023 Apr;22(4):273-294. doi: 10.1038/s41573-022-00618-w. Epub 2023 Jan 24.
5
PTPN2 in the Immunity and Tumor Immunotherapy: A Concise Review.PTPN2 在免疫和肿瘤免疫治疗中的作用:简要综述。
Int J Mol Sci. 2022 Sep 2;23(17):10025. doi: 10.3390/ijms231710025.
6
Combination Approaches to Target PD-1 Signaling in Cancer.癌症中靶向 PD-1 信号的联合治疗方法。
Front Immunol. 2022 Jul 14;13:927265. doi: 10.3389/fimmu.2022.927265. eCollection 2022.
7
Macrophage Membrane-Camouflaged shRNA and Doxorubicin: A pH-Dependent Release System for Melanoma Chemo-Immunotherapy.巨噬细胞膜伪装的短发夹RNA和阿霉素:一种用于黑色素瘤化学免疫治疗的pH依赖性释放系统。
Research (Wash D C). 2022 Feb 8;2022:9768687. doi: 10.34133/2022/9768687. eCollection 2022.
8
Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.靶向蛋白酪氨酸磷酸酶 22 并不能增强嵌合抗原受体 T 细胞在实体瘤中的疗效。
Mol Cell Biol. 2022 Mar 17;42(3):e0044921. doi: 10.1128/MCB.00449-21. Epub 2022 Jan 18.
9
Structural characterization of a pathogenic mutant of human protein tyrosine phosphatase PTPN2 (Cys216Gly) that causes very early onset autoimmune enteropathy.一种导致非常早发性自身免疫性肠病的人蛋白酪氨酸磷酸酶 PTPN2(半胱氨酸 216 甘氨酸)致病性突变体的结构特征。
Protein Sci. 2022 Feb;31(2):538-544. doi: 10.1002/pro.4246. Epub 2021 Nov 27.
10
Loss of protein tyrosine phosphatase non-receptor type 2 reduces IL-4-driven alternative macrophage activation.蛋白酪氨酸磷酸酶非受体型 2 的缺失减少了 IL-4 驱动的替代型巨噬细胞活化。
Mucosal Immunol. 2022 Jan;15(1):74-83. doi: 10.1038/s41385-021-00441-3. Epub 2021 Aug 21.